D.E. Shaw & Co
OPNT

D.E. Shaw & Co’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

D.E. Shaw & Co’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,044
Closed -$120K – 5713
2022
Q2 		$120K Sell
10,044
-6,945
-41% -$112K ﹤0.01% 4691
2022
Q1 		$364K Buy
+16,989
New +$450K ﹤0.01% 4554

Other funds holding OPNT

HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's OPNT Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q3 2022, closing a stake of 10,044 shares — an estimated $120K sold.

D.E. Shaw & Co first reported a position in OPNT in Q1 2022 and held it in 2 quarters. The position peaked at $364K in Q1 2022. 32 funds tracked by Wall St. Rank hold OPNT as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 10,044 Opiant Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $120K.
  • D.E. Shaw & Co first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • D.E. Shaw & Co's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $364K in Q1 2022.
  • 32 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.